Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
New immunization study findings have been reported by researchers at University of Hong Kong, Department of Microbiology
May 14th, 2008
Investigators publish new data in the report 'Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.' "Development of vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is crucial in the prevention of SARS reemergence. The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines," scientists in People's Republic of China report. "Our previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV)...
Source: Vaccine Weekly (2008-05-14)
|
